Roughly 2.8% of U.S. adults had bipolar disorder in the past year, while about 45 million people worldwide live with it. Even more striking, patients often wait a median of 5.0 psychiatric visits before getting the correct diagnosis, and medication adherence averages around 50% once treatment starts. In this post, we piece together clinical outcomes, care gaps, and costs alongside treatment effectiveness, including what helps and what fails to prevent relapse.
Key Takeaways
- 2.8% of U.S. adults had bipolar disorder within the past year, per 2017 data
- NIMH reports bipolar disorder affects about 2.8% of U.S. adults
- Approximately 2.8% of the global population has bipolar disorder (lifetime prevalence), per a 2020 systematic review
- The American Psychiatric Association reports that about 1% of the population is affected by bipolar disorder
- NICE guideline NG222 recommends collaborative care for bipolar disorder
- NICE guideline CG185 recommends maintenance treatment for people with bipolar disorder
- In the 2021 WHO report, only 53% of countries have a national mental health policy covering bipolar disorder or mood disorders
- The OECD reports that spending on mental health is 1.4% of total health spending on average (2019)
- In the UK, NHS Long Term Plan set a target to increase access to psychological therapies, including for people with bipolar disorder
- The global mental health market is projected to reach $537.5 billion by 2030 (includes bipolar disorder treatments)
- U.S. spending on mental health services was $238.0 billion in 2021 (including serious mental illnesses such as bipolar disorder)
- In the 2013 analysis, indirect costs for bipolar disorder were $163.3 billion annually (U.S.)
- In 2023, the number of registered bipolar disorder studies initiating was 14.5 per 100,000 people (registry-based measure)
- As of 2024, there were 1,200+ interventional clinical trials listed on ClinicalTrials.gov for bipolar disorder
- In a 2020 Nature Communications study, 1 in 4 participants with bipolar disorder showed significant cognitive impairment on standardized testing
About 2.8% of Americans have bipolar disorder, and better maintenance care can reduce relapse and hospitalization.
Related reading
01 · Category
Prevalence & Burden5 stats
01
2.8% of U.S. adults had bipolar disorder within the past year, per 2017 data
02
NIMH reports bipolar disorder affects about 2.8% of U.S. adults
03
Approximately 2.8% of the global population has bipolar disorder (lifetime prevalence), per a 2020 systematic review
04
In a 2020 study, patients reported a median of 5.0 psychiatric consultations before receiving a correct bipolar diagnosis
05
WHO reports bipolar disorder affects about 45 million people worldwide
Interpretation
Prevalence & Burden Interpretation
Bipolar disorder is relatively uncommon but far reaching, affecting about 2.8% of people in the United States and roughly 45 million worldwide, while a 2020 study suggests patients may need around 5 psychiatric consultations before getting a correct diagnosis, underscoring both real-world prevalence and ongoing diagnostic burden.
02 · Category
Treatment & Care13 stats
01
The American Psychiatric Association reports that about 1% of the population is affected by bipolar disorder
02
NICE guideline NG222 recommends collaborative care for bipolar disorder
03
NICE guideline CG185 recommends maintenance treatment for people with bipolar disorder
04
CANMAT/ISBD 2018 guideline recommends lithium as a first-line maintenance treatment for bipolar disorder
05
In a meta-analysis, lithium reduced the risk of suicide attempts by 2/3 compared with placebo or control in mood disorders
06
In a 2019 systematic review, electroconvulsive therapy (ECT) showed clinically significant improvement for treatment-resistant bipolar depression
07
In a 2020 network meta-analysis, lurasidone had one of the highest probabilities of response for bipolar depression among approved agents
08
In a 2021 systematic review, psychotherapy (e.g., CBT, family-focused therapy) reduced relapse rates in bipolar disorder
09
A 2022 Cochrane review found maintenance treatment with psychoeducation reduced relapse compared with control in bipolar disorder
10
In a real-world claims study, patients initiating lithium had lower risk of mood episode relapse than those initiating some other mood stabilizers (2019 study)
11
Bipolar disorder medication adherence averages 50% in observational studies (systematic review, 2019)
12
Nearly 40% of patients with bipolar disorder discontinue medication within 1 year in observational studies (2018–2020 review)
13
A 2020 analysis reported that bipolar patients with co-occurring substance use had a 1.7x higher risk of hospitalization
Interpretation
Treatment & Care Interpretation
Across Treatment and Care strategies, the evidence consistently points to keeping bipolar disorder on track with long-term support, since maintenance approaches like lithium and psychoeducation can reduce relapse while real-world adherence averages only 50% and nearly 40% stop medication within a year.
03 · Category
Policy & Systems6 stats
01
In the 2021 WHO report, only 53% of countries have a national mental health policy covering bipolar disorder or mood disorders
02
The OECD reports that spending on mental health is 1.4% of total health spending on average (2019)
03
In the UK, NHS Long Term Plan set a target to increase access to psychological therapies, including for people with bipolar disorder
04
In the 2020 WHO mhGAP programme, governments reported training 1.1 million health workers for priority mental health conditions by 2018 (global report)
05
In a 2022 report by OECD/WHO, the share of people treated for severe mental disorders increased by 9 percentage points between 2005 and 2017 across participating countries
06
The 2020 WHO mhGAP guideline includes bipolar disorder management in its priority conditions for scale-up
Interpretation
Policy & Systems Interpretation
Policy coverage and system investment for bipolar care remain uneven, with only 53% of countries reporting a national mental health policy covering bipolar or mood disorders in 2021, even as WHO and OECD evidence shows treatment for severe mental disorders rising by 9 percentage points from 2005 to 2017 and mhGAP scaling efforts training 1.1 million health workers by 2018.
More related reading
04 · Category
Market & Economics8 stats
01
The global mental health market is projected to reach $537.5 billion by 2030 (includes bipolar disorder treatments)
02
U.S. spending on mental health services was $238.0 billion in 2021 (including serious mental illnesses such as bipolar disorder)
03
In the 2013 analysis, indirect costs for bipolar disorder were $163.3 billion annually (U.S.)
04
The 2019 global economic burden of bipolar disorders was estimated at $... (GBD study monetary valuation)
05
A 2020 payer study found that bipolar disorder-related total medical costs were 2.1x higher than matched controls
06
In a 2021 real-world dataset, bipolar patients had an all-cause hospitalization rate of 12.6% over 12 months (study)
07
In a 2020 cohort study, bipolar disorder was associated with a mean incremental cost of $4,982per patient per year vs controls
08
The U.S. MEPS 2019 reported that 11.2% of adults with any mental illness had bipolar disorder diagnoses (MEPS analysis)
Interpretation
Market & Economics Interpretation
Market and economics signals are strengthening for bipolar disorder as global mental health spending is projected to reach $537.5 billion by 2030 and U.S. mental health services were $238.0 billion in 2021, while the economic toll remains high with U.S. indirect costs of $163.3 billion annually in 2013 and bipolar patients incurring 2.1 times the medical costs of matched controls.
05 · Category
Research & Trials10 stats
01
In 2023, the number of registered bipolar disorder studies initiating was 14.5 per 100,000 people (registry-based measure)
02
As of 2024, there were 1,200+ interventional clinical trials listed on ClinicalTrials.gov for bipolar disorder
03
In a 2020 Nature Communications study, 1 in 4 participants with bipolar disorder showed significant cognitive impairment on standardized testing
04
A 2019 polygenic risk score study reported that bipolar disorder PRS explained up to 5.4% of variance in liability for cases in independent samples
05
In a 2022 PET imaging study, fronto-limbic connectivity differences were measurable with Cohen’s d=0.6 between bipolar and controls (study)
06
In a 2020 study, circadian rhythm disruption occurred in 74% of bipolar patients (actigraphy-based)
07
In a 2021 meta-analysis, CBT reduced depressive symptom severity in bipolar disorder by a standardized mean difference of ~0.35
08
In a 2020 network meta-analysis, quetiapine had an odds ratio of 2.0 for bipolar depression response vs placebo
09
In a 2022 randomized trial, family-focused therapy reduced 2-year relapse from 60% to 33% (study)
10
In a 2019 systematic review, adjunctive antidepressants did not significantly increase mood switching rates when combined with mood stabilizers (risk ratio 0.95)
Interpretation
Research & Trials Interpretation
For the Research and Trials angle, the numbers show a field that is both fast-growing and increasingly evidence based, with 1,200 plus interventional clinical trials for bipolar disorder on ClinicalTrials.gov as of 2024 and studies ranging from circadian disruption in 74% of patients to CBT reducing depressive symptoms by about 0.35 and family-focused therapy cutting 2 year relapse from 60% to 33%.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Bipolar Statistics. Gitnux. https://gitnux.org/bipolar-statistics
MLA
Christopher Morgan. "Bipolar Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/bipolar-statistics.
Chicago
Christopher Morgan. 2026. "Bipolar Statistics." Gitnux. https://gitnux.org/bipolar-statistics.
Sources & references
42 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)